Zhang, YiShen, GuoyiXu, RongyuHuang, GuozhongHuang, ZhijunDuan, HongbingYang, ShengshengZheng, QingfengYang, LibaoLiu, RongxingMa, LiangyunChen, ShaogengYi, YunfengZhang, ZhemingLi, KezhiBirdas, Thomas J.Koyanagi, KazuoSimone, Charles B., II2024-05-132024-05-132023Zhang Y, Shen G, Xu R, et al. Effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with esophageal squamous cell carcinoma: a prospective multicenter observational cohort study. J Thorac Dis. 2023;15(11):6228-6237. doi:10.21037/jtd-23-1408https://hdl.handle.net/1805/40690Background: Camrelizumab has been demonstrated to be a feasible treatment option for locally advanced esophageal squamous cell carcinoma (ESCC) when combined with neoadjuvant chemotherapy. This trial was conducted to investigate the effectiveness and safety of camrelizumab-containing neoadjuvant therapy in patients with ESCC in daily practice. Methods: This prospective multicenter observational cohort study was conducted at 13 tertiary hospitals in Southeast China. Patients with histologically or cytologically confirmed ESCC [clinical tumor-node-metastasis (cTNM) stage I-IVA] who had received at least one dose of camrelizumab-containing neoadjuvant therapy were eligible for inclusion. Results: Between June 1, 2020 and July 13, 2022, 255 patients were enrolled and included. The median age was 64 (range, 27 to 82) years. Most participants were male (82.0%) and had clinical stage III-IVA diseases (82.4%). A total of 169 (66.3%) participants underwent surgical resection; 146 (86.4%) achieved R0 resection, and 36 (21.3%) achieved pathological complete response (pCR). Grades 3-5 adverse events (AEs) were experienced by 14.5% of participants. Reactive cutaneous capillary endothelial proliferation occurred in 100 (39.2%) of participants and all were grade 1 or 2. Conclusions: Camrelizumab-containing neoadjuvant therapy has acceptable effectiveness and safety profiles in real-life ESCC patients.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalEsophageal squamous cell carcinoma (ESCC)Neoadjuvant therapyCamrelizumabReal worldArticle